logo
Menu
Innovation Observatory > Reports > Gynaecology, Women's Sexual Health and Benign Breast Disease

Results

Drugs

July 2018

Leuprorelin acetate for the preservation of ovarian function in premenopausal women with neoplastic disease undergoing chemotherapy

Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) analogue that may preserve ovarian function by preventing early stage development of ovarian follicles from maturation. This may decrease the number of follicles that are vulnerable to chemotherapy. The protective effects of GnRH analogues have also been associated with a decrease in utero-ovarian blood flow which leads to decreased exposure of the ovaries to the chemotherapeutic agents. If licensed, leuprorelin acetate, given by injection, may offer a simpler, less invasive and less expensive alternative when compared to current strategies for preserving ovarian function in women undergoing chemotherapy.

Diagnostics

November 2016

FlexDex Needle Driver for minimally invasive laparoscopic surgical suturing

The FlexDex Needle Driver, developed by FlexDex, Inc., is a laparoscopic instrument intended for use in all patients undergoing laparoscopic surgical procedures requiring intensive suturing.

Devices

September 2015

Sonata™ System for the removal of uterine fibroids

The Sonata™ System (previously VizAblate®), developed by Gynesonics, is an incisionless, transcervical system that combines ultrasound image guidance with radiofrequency (RF) ablation. The system is designed to treat symptomatic uterine fibroids in a hospital outpatient setting, depending on anaesthetic requirements.

Devices

November 2014

SoftVue™ system for diagnostic breast imaging

The SoftVue™ system developed by Delphinus Medical Technologies is a non-ionising, non-compressing, and non-invasive whole breast imaging device. Its intended use is for the examination of breasts for the presence of suspicious masses. It is not intended for use as a replacement of screening mammography.

Devices

March 2014

Lyrette™ for stress urinary incontinence

Lyrette™, formerly known as Renessa, is a transurethral device developed by Verathon Medical Ltd to deliver non-ablative radiofrequency energy to women with stress urinary incontinence (SUI) caused by hypermobility. It is intended to provide a treatment option for SUI before invasive surgery.

Diagnostics

August 2013

PartoSure™ Time to Delivery test in suspected premature labour

PartoSure™ Time to Delivery (TTD) test is a novel, rapid point-of-care test, developed by AmniSure International (a QIAGEN company). The test is designed to help predict the time to delivery when pregnant women report signs and symptoms suggestive of labour between 20 and 37 weeks of gestation with clinically intact amniotic membranes.

Devices

August 2013

IceSense3™ Cryoablation System for breast fibroadenoma

The IceSense3™ Cryoablation System, developed by IceCure Medical Ltd., is a device which uses extreme cold (cryoablation) to treat symptomatic breast fibroadenoma (benign breast tumour).

Devices

July 2013

IUB™ SCu300A intrauterine device for contraception

The IUB™ SCu300A is an intrauterine device (IUD) intended for women who need long-acting reversible contraception. It is in development by Ocon Medical Ltd. The device is made from memory metal, also called shape memory alloy, and copper. It is designed to work in a similar way to other IUDs by stopping the sperm and …

Drugs

January 2013

Ospemifene for vulvo-vaginal atrophy in postmenopausal women

Ospemifene is intended to be used as first or second line therapy for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. If licensed, it may provide an alternative treatment option for this patient group. Ospemifene is an orally active, selective oestrogen receptor modulator (SERM) with agonistic effects on vaginal epithelium in post-menopausal women. It …

Diagnostics

May 2012

HPV OncoTect® E6 E7 mRNA Assay to guide colposcopy referral in cervical cancer screening

HPV OncoTect® E6 E7 mRNA Assay is a laboratory test (based on in situ hybridisation and flow cytometry) that may improve the accuracy with which women who are at increased risk of developing cervical cancer are identified following routine screening. The test detects how much of a marker for early pre-cancerous changes, called HPV E6 …

Get Alerts